Navigation Links
Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Date:11/4/2007

bert A. Harrington, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Clinical Research Institute. "I'm looking forward to seeing data from phase II and phase III studies with the REG1 drug:antidote system."

"The data from the Phase 1c study addressed important questions, particularly regarding the ability to titrate the RB007 component and therefore 'dial down' the anticoagulant effect of RB006," stated Doug Gooding, Chief Executive Officer of Regado Biosciences. "Based upon our Phase I study results, we developed an extensive Phase II program to evaluate REG1 in a variety of coronary revascularization settings. The first study is actively enrolling patients and we expect to initiate several additional studies over the coming months."

REVERSAL-PCI, a multi-center, open-label, randomized Phase IIa clinical study of the REG1 anticoagulation system, will enroll 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting in patients at low risk for complications associated with therapy-related bleeding or heart attack.

About REG1 Anticoagulation System

Regado's lead product candidate, REG1, is the first specific, direct- acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at a high-risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant co
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  Amgen (NASDAQ: ... first quarter financial results on Tuesday, April 21, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:4/16/2015)... 2015 Today, Kenneth C. Frazier , chairman ... was elected chairman of the Board of the Pharmaceutical Research ... president and CEO John J. Castellani announced that ... New Officers Elected to PhRMA Board Frazier ... C. Read , chairman and CEO of Pfizer, Inc. Also ...
(Date:4/16/2015)... 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) announced ... with a newly formed specialty healthcare company focused ... addressing urological disorders. The merged company, which is ... commenced operations and incorporates the pipeline assets of ... strategy is to build a late-stage and commercial ...
Breaking Medicine Technology:Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
(Date:4/18/2015)... April 18, 2015 Carinsurancehints.com has released a ... plans that offer financial protection against fire damage. ... pay benefits in case their vehicle is set intentionally on ... caused by rioting or by other things. , It ... on a single website http://www.carinsurancehints.com/ , in just ...
(Date:4/18/2015)... PITTSBURGH, PA (PRWEB) April 18, 2015 ... so I decided to create a healthful juice ... an inventor from Rosedale, Md. "It increases my ... overall healthy body." , He developed Tapp's Juice ... The juice helps to prevent physical and mental ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog post explaining ... , Clients can review important auto insurance quotes ... provides important advantages for clients who need affordable financial ... not have coverage for their vehicles can purchase a ... hour. Many agencies offer important discounts and drivers can ...
(Date:4/18/2015)... has released a new blog post explaining how to ... , Drivers can find accurate information about various auto ... website can help drivers compare the newest and best ... whole process is designed to be convenient, free and ... quotes is advantageous because it allows clients to find ...
(Date:4/18/2015)... York, New York (PRWEB) April 18, 2015 ... ) filed on behalf of individuals who were ... replacement system continue to move forward in the U.S. ... Order dated April 10th, the Court has amended an ... of unrelated cases. Among other things, the new amendment ...
Breaking Medicine News(10 mins):Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... BATESVILLE, Ind., Feb. 8 Hillenbrand,Industries, Inc. (NYSE: ... of $0.285 per share. This dividend was declared by ... payable on March 31, 2008 to,shareholders of record at ... ABOUT HILLENBRAND INDUSTRIES, INC., Hillenbrand Industries is organized ...
... sees greater activation of key brain region than found in ... a video game "widow," science might now be able to ... shows that the part of the brain associated with reward ... when both genders played a game whose object was to ...
... 3 Program of CGT-2168, MENLO PARK, ... named a distinguished international panel of medical ... charged with overseeing COGENT,the company,s global Phase ... antiplatelet product CGT-2168., (Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ...
... happy and healthy ... control, WESTPORT, Conn., Feb. 8 Just in ... diabetes information,inspiration, and connection, has a spicy and informative ... people with diabetes.,Accessible at http://www.dlife.com/diabetes-valentines, the quiz ...
... sales of $20.4 million versus $24.1 ... million in the same quarter last year., - ... initial shipments expected during the second half of fiscal 2008., ... ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer and marketer ...
... Stereotaxis, Inc. (Nasdaq:,STXS), announced today that Bevil ... Chief Financial Officer, will present at the Deutsche ... Carlton Hotel in Naples,Florida on Thursday, February 14, ... at the conference is by invitation only. The ...
Cached Medicine News:Health News:For Males, Video Game Rewards Are All in the Mind 2Health News:For Males, Video Game Rewards Are All in the Mind 3Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 2Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 3Health News:Love and Diabetes: dLife Valentine's Day Quiz Tests and Teaches Important Relationship Lessons for People With Diabetes 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 3Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 4Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 5
For the quantitative in vitro determination of Carbamazepine in human serum...
For the quantitative in vitro determination of Phenobarbital in human serum....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with particulate (silica) activator....
Medicine Products: